ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
22 Novembro 2022 - 11:00AM
ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in
Out-of-Hospital Care Management Software Solutions
ResMed (NYSE: RMD, ASX: RMD) today announced it has completed its
€958.6 million acquisition of MEDIFOX DAN, a German leader in
software solutions for a wide variety of out-of-hospital care
providers.
MEDIFOX DAN is headquartered in Hildesheim, Germany, with over
700 employees. It now operates under its current brand within the
ResMed SaaS business segment. Its administrative, financial, and
operational solutions are mission-critical for out-of-hospital care
providers, providing care documentation, personnel planning,
administration, billing, and more – similar to the solutions of
ResMed’s leading U.S. SaaS brands, MatrixCare and Brightree.
“We’re excited to have closed this important expansion of our
SaaS business, and to officially welcome MEDIFOX DAN to our ResMed
SaaS team and global ResMed family,” said ResMed CEO Mick Farrell.
“MEDIFOX DAN is a German leader in software innovation, united with
the rest of ResMed in its mission to improve tens of millions of
people’s lives through technology. Today, its strong offerings and
dedicated staff expand ResMed’s out-of-hospital SaaS business into
new health sectors, and to build on our strong ResMed healthcare
business in Germany, the world’s second largest healthcare market
in per capita spending.”
“Starting today, we are continuing our success story as part of
the ResMed family,” said MEDIFOX DAN Co-Managing Directors Dr.
Thorsten Schliebe and Christian Städtler. “With ResMed, we have
found an ideal partner –global leaders in digital health,
cloud-based SaaS solutions with emphasis on innovation, data
privacy and data security – with which we can continue to grow,
develop, and provide our customers with secure, state-of-the-art
software solutions and services, so they can navigate the
challenges of their daily caregiving routines in the best possible
way.”
ResMed intends to retain MEDIFOX DAN’s employees, locations, and
business processes. MEDIFOX DAN will report into ResMed SaaS
President Bobby Ghoshal.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms
support the professionals and caregivers who help people stay
healthy in the home or care setting of their choice. By enabling
better care, we improve quality of life, reduce the impact of
chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more, visit ResMed.com
and follow @ResMed.
About MEDIFOX DANThe MEDIFOX DAN Group,
headquartered in Hildesheim, Germany, currently employs over 700
people at nine locations nationwide and specializes in the
development of innovative software solutions and services for
professional and non-professional care, therapeutic practices and
child, family, and youth welfare facilities. In addition, digital
solutions for modern training and education management - both for
professional care and family caregivers - expand the group's
comprehensive product portfolio. What started as a small start-up
developed into a firmly established software company. Besides
holistic product solutions, MEDIFOX DAN has always been
characterized by strong partnerships and innovative services.
Behind MEDIFOX DAN stands a team of innovative minds, over 55 years
of industry experience and cumulative expertise, that works every
day to set trendsetting standards for digitization in the health
and social care sector and to drive innovation forward. In short:
We are more than just software.
For mediaIn Germany:
resmedGER@allisonpr.com Rest of world: Jayme
Rubenstein, +1 508.769.8440, news@resmed.com
For investorsAmy Wakeham, +1 858.836.5000,
investorrelations@resmed.com
Resmed (LSE:0KW4)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Resmed (LSE:0KW4)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024